I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Cancer of the prostate is the second most frequently diagnosed cancer in men worldwide and the most frequently diagnosed noncutaneous cancer.\[[@ref1][@ref2]\] Nearly, a million new cases were diagnosed in 2008 worldwide.\[[@ref1][@ref2]\] Several other studies \[[@ref3][@ref4][@ref5][@ref6]\] have shown the significant prevalence of prostate cancer and possible mortality associated with it, thus procedures for early diagnosis and prompt treatment cannot be overemphasized.

Prostate needle biopsy is the standard procedure for the diagnosis of carcinoma of the prostate, and transrectal ultrasound-guided prostate biopsy (TRUSPB) is the most commonly used approach. However, the procedure may result in infective complications due to the possibility of bacterial translocation from the rectum to the prostate, blood, and other parts of the urogenital tract.

Empirical antibiotic (EA) prophylaxis with a fluoroquinolone is usually given to prevent infective complication. This has been reported to reduce infective complications to 8% compared with placebo which is 25%.\[[@ref7]\] Recent studies have demonstrated an increased incidence of infective complications following prostate biopsy using empirical antibiotics (EA).\[[@ref8][@ref9][@ref10][@ref11]\] It has also been reported that the rate of infective complications requiring hospitalization is significantly greater in more recent years.\[[@ref12]\] These infective complications may be severe leading to urosepsis and death. The reason for the increase in biopsy infective complications appears to be due to the increase in the incidence of fluoroquinolone-resistant bacteria \[[@ref13][@ref14][@ref15]\] and the lack of an evidence-based standardized protocol of antibiotic prophylaxis for transrectal prostate biopsy (TRPB).

Targeted antibiotic (TA) prophylaxis based on the rectal swab result has been shown to effectively reduce postbiopsy infective complications, and it is as well cost-effective in the long run.\[[@ref16]\] Therefore, the identification of prebiopsy rectal microbes, culture, and antibiotic sensitivity pattern and the choice of the appropriate antibiotics will reduce the incidence of postbiopsy infective complications, hospital admission, and the attendant high cost of treatment. The aim of this study was, therefore, to compare the infective complications following empirical and targeted prophylactic antibiotic use in patients undergoing TRPB.

P[ATIENTS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
================================================

Patients attending the urology clinic of Lagos State University Teaching Hospital and had indications (elevated serum prostate-specific antigen \[PSA\] and or digital rectal examination suspicious of prostate cancer) for ultrasound-guided transrectal prostate biopsy were randomized into two groups: TAs and EAs. Patients had prebiopsy urinalysis and urine culture. Those with prebiopsy abnormal urinalysis or urinary tract infection, recent antibiotic use in the preceding 3 months, and past history of fluoroquinolone adverse reaction were excluded from the study. Aspirin use was discontinued 10 days before the biopsy.

The rectal swab was collected from all the patients in the clinic 5 days before the biopsy to allow adequate time for results; the collection was done with sterile swab sticks and transported to the laboratory immediately. The swab was inoculated on MacConkey agar and incubated at 35°C--37°C for 18--24 h. Mixed cultures were separated, and pure isolates were kept inside peptone for further identification. Thereafter, Gram staining was done to group the organisms into Gram positive or Gram negative and was further tested for antibiotic sensitivity. Antibiotic susceptibility test was done using Kirby--Baker method on Mueller--Hinton agar. The laboratory investigations were done by the same microbiologist in our laboratory. The TA group had intravenous antibiotics based on the rectal swab culture sensitivity and the EA group had the usual intravenous ciprofloxacin 200 mg within 1 h before the biopsy. TRUSPB was done under caudal anesthesia with CHISON 8300 digital ultrasound diagnostic B/Wsystem (Chison Medical Imaging Limited, China) using a disposable sterile, size 18G, trucut needle (AGUJA semi-automatic needle, Italy) for each patient. Twelve cores were taken from each patient. They were discharged home after the procedure and were followed up weekly for 4 weeks. All the patients also had postbiopsy urinalysis and urine culture. During each visit, the patients were asked if they had dysuria or fever, their vital signs were assessed, and any temperature \>38°C was recorded as fever. They also had urinalysis and urine m/c/s weekly for 4 weeks. Blood culture was also done in those whose temperature was \>38°C and who had sepsis.

Other clinical data obtained included family history of prostate cancer, serum PSA, comorbidities (hypertension and diabetes), prostate size measured with transrectal ultrasound scan, histopathology of the biopsy specimen, and stage of the disease for those with prostate cancer.

SPSS software version 21 for Windows (SPSS, Inc., Chicago, IL, USA) was used for data analysis. Chi-square test or Fisher\'s exact test was used to compare categorical variables, whereas Student\'s *t*-test was used to compare means of numerical variables. Multiple logistic regression was used to evaluate for the potential risk factor for the development of postbiopsy sepsis. For all statistical tests, confidence interval was set at 95% and statistical tests were considered significant if *P* \< 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Study population {#sec2-1}
----------------

There were 112 patients who were recruited for the study, but only 100 who made the inclusion criteria were included in the analysis. There were fifty patients in each group (EA vs. TA groups). The patients were aged 44--85 (mean = 66.0) years. [Figure 1](#F1){ref-type="fig"} shows the age group distribution of the patients, with men of 60--69 years accounting for 50% of the study population.

![Age distribution of patients](AAM-18-132-g001){#F1}

Comparison of the two groups of TA and EA prophylaxis is shown in [Table 1](#T1){ref-type="table"}. Essentially, there was no significant difference between the two groups with regard to age, serum PSA, prostate size, family history of prostate cancer, history of diabetes, histopathological diagnosis, and stage of the disease.

###### 

Comparison of the two groups of patients (empirical and targeted antibiotic groups)

  Variable                 Targeted (*n*=50)   Empirical (*n*=50)   Total (*n*=100)   *P*
  ------------------------ ------------------- -------------------- ----------------- -------
  Age                                                                                 
   40-49                   4                   1                    4                 0557
   50-59                   15                  34                   65                
   60-69                   50                  15                   31                
   70-79                   24                                                         
   80-89                   7                                                          
  PSA                                                                                 
   \<4.0                   1                   0                    1                 0.662
   4.0-10                  19                  18                   37                
   10-20                   21                  23                   44                
   20-100                  1                   3                    4                 
   \>100                   8                   6                    14                
  Prostate size                                                                       0.201
   \<40                    4                   1                    5                 
   40-100                  19                  26                   45                
   \>100                   27                  23                   50                
  Histology                                                                           
   BPH                     35                  36                   71                0.662
   Adenocarcinoma          15                  14                   29                
  LUTS                                                                                
   Yes                     41                  50                   91                0.002
   No                      9                   0                    9                 
  Comorbidity (diabetes)                                                              
   Yes                     10                  12                   22                0.629
   No                      40                  38                   78                
  Metastasis                                                                          
   Yes                     4                   3                    7                 0.695
   No                      46                  47                   93                
  Postbiopsy infection                                                                
   Yes                     1                   5                    6                 0.042
   No                      49                  45                   94                

PSA=Prostate-specific antigen, LUTS=Lower urinary tract symptoms, BPH=Benign prostatic hyperplasia

Prebiopsy rectal flora and antibiotic sensitivity for all patients {#sec2-2}
------------------------------------------------------------------

[Figure 2](#F2){ref-type="fig"} shows the organism identified in the rectal flora, with *Providencia stuartii*, *Escherichia coli*, *and* *Citrobacter freundii* being the three most predominant. Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} show the antibiotic sensitivity and resistant patterns of the organisms identified in the rectal flora, levofloxacin being the antibiotic that showed the highest sensitivity. There were 17 fluoroquinolone-resistant *E. coli* from the rectal swab culture, 15.8% were levofloxacin resistant, whereas 73.7% were resistant to ciprofloxacin.

![The prebiopsy bacterial flora of the rectum of all the patients](AAM-18-132-g002){#F2}

![The prebiopsy antibiotic sensitivity pattern of the bacteria in the rectum of all the patients](AAM-18-132-g003){#F3}

![The prebiopsy antibiotic resistant pattern of the bacteria in the rectum of the patients](AAM-18-132-g004){#F4}

Incidence of postbiopsy sepsis and antibiotic sensitivity pattern {#sec2-3}
-----------------------------------------------------------------

Of the fifty patients who had TA prophylaxis, one (2%) had positive postbiopsy urine culture, but there was no patient with febrile (symptomatic) urinary tract infection in this group. Conversely, among the fifty patients with EA prophylaxis, five (10%) had positive urine culture postbiopsy; three (6%) of whom had fever, chills, rigors, and required hospitalization, whereas the remaining two (4%) had only positive urine culture postbiopsy. Prophylactic antibiotic status was found to be a significant factor to the development of postbiopsy sepsis (*P* = 0.042).

The six patients who had postbiopsy infection had the prebiopsy rectal swab culture yielded *E. coli* resistant to the ciprofloxacin. The postbiopsy urine culture of these six patients yielded *E. coli* sensitive to levofloxacin, ceftriaxone, ceftazidime, and cefexime.

Risk factor for postbiopsy sepsis {#sec2-4}
---------------------------------

The risk factor for postbiopsy sepsis was evaluated using multiple logistic regression \[[Table 2](#T2){ref-type="table"}\]. The prophylactic antibiotic status and the comorbidity of diabetes were found to be significant risk factors for sepsis. The risk for sepsis was 5.6 folds greater when EA prophylaxis was used compared to TA prophylaxis. In addition, men with diabetes have 22-fold increase in the incidence of sepsis following TRPB. The age, serum PSA, histology, lower urinary tract symptoms, and prostate size were not found to be significant risk factors for sepsis.

###### 

Risk factors for postbiopsy infection

  Variable                                      Univariate (*P*)   Multivariate (*P*)   OR       95% CI of OR
  --------------------------------------------- ------------------ -------------------- -------- ----------------
  Age                                           0.084              0.162                0.051    0.970, 9.290
  Prostate size                                 0.832              0.986                1.289    0.003, 9.923
  Serum PSA                                     0.061              0.834                2.772    0.042, 6.984
  Histology                                     0.247              0.335                2.634    0.368, 18.842
  LUTS                                          0.623              0.995                2.754    0.345, 11.678
  Antibiotic group: Targeted versus empirical   0.042              0.045                5.596    1.390, 38.108
  Comorbidity                                   0.000              0.008                22.213   2.278, 216.612

CI=Confidence interval, OR=Odds ratio, PSA=Prostate-specific antigen, LUTS=Lower urinary tract symptoms, BPH=Benign prostatic hyperplasia

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

TRPB is currently the standard tissue-sampling technique for the histological diagnosis of cancer of the prostate. It is one of the most commonly performed urological procedures, with over a million patients reportedly undergoing prostate biopsy every year in the United States.\[[@ref17]\] Although TRPB is generally considered a safe procedure, it has its own attendant complications ranging from minor problems such as pain, hematospermia, hematuria, and hematochezia to severe infectious complications such as urosepsis and acute prostatitis.\[[@ref9]\]

There are two primary antibiotic prophylaxis strategies that have emerged over time to prevent postbiopsy-related infections, namely an EA or TA approach.\[[@ref18]\] This study was designed to evaluate the infectious complication rate in a selected cohort of men who received a rectal swab culture and subsequent TA prophylaxis, compared to a group of same-risk men who had EA prophylaxis with ciprofloxacin before TRPB. The rationale for the use of rectal cultures to identify culpable organisms for appropriate antibiotics to be given in targeted prophylactic antibiotic use was formulated due to the increasing incidence of postbiopsy infective complications in EA prophylaxis for TRPB. In addition, inappropriate use of antibiotics is also a risk for the development of antibiotic resistance.

The findings from this study showed that the rate of infective complication was lower in the TA prophylactic group compared to the EA group (2% vs. 10%). This decrease in infective rate has been reported in similar studies in literature.\[[@ref16][@ref19][@ref20][@ref21][@ref22]\] The incidence of urosepsis in the TA group was 0% compared to 6% in the EA group. In a similar study, with empiric single-drug antimicrobial prophylaxis for TRPB, the hospitalization rate for infections was 0%--6.3%,\[[@ref23]\] which is similar to the result from our study. Dai *et al*.\[[@ref21]\] and Summers *et al*.\[[@ref22]\] have documented infective complication rates of 1.9% and 0.6%, respectively, among patients who had TA prophylaxis, whereas Duplesis\'s study \[[@ref19]\] showed 2.9% infection rates among the EA group.

Furthermore, the presence of fluoroquinolone-resistant bacteria in the rectal flora increases the rate and potential severity of postbiopsy infections by 5 folds in patients receiving empiric fluoroquinolone prophylaxis.\[[@ref24]\] Our study showed that fluoroquinolone-resistant organisms (two isolates of *E. coli*, two isolates of *P. stuartii*, and two isolates of *C. freundi*) were responsible for infection in all the six patients. In addition, this risk of postbiopsy infection was increased by 5.6 folds among the EA group compared to the TA group.

This finding supports the utilization of prebiopsy rectal cultures to identify patients at increased risk and to select targeted prophylaxis that is most likely to be effective. This corroborates other findings in the literature that fluoroquinolone-resistant bacteria are responsible for the increase in postbiopsy infective complications.\[[@ref10][@ref14][@ref15]\] Furthermore, in all the six cases of postbiopsy infection, the bacterial isolates were all resistant to ciprofloxacin.

In addition, patients with comorbidity of diabetes are particularly at risk. The risk of postbiopsy infection increased 22 folds among patients undergoing TRPB if they were diabetic.

Therefore, the use of rectal swab cultures for TA prophylaxis will reduce infective complications compared to EA prophylaxis which may be associated with more infective complications and antibiotic resistance. In addition, when EA prophylaxis must be considered at all, levofloxacin would be a much better choice than ciprofloxacin because of the less resistance pattern from the rectal bacterial flora.

Reducing the postbiopsy infection would lead to less hospitalization and reduced morbidity and mortality following TRPB. In addition, TA prophylaxis for patients undergoing TRPB would potentially reduce the overall cost of treatment, especially in a resource-limited environment like ours, which is very important.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

Targeted antimicrobial prophylaxis achieved a lower rate of infectious complications in patients who had prostate biopsy. This finding suggests that this individualized method of prophylaxis should be considered for patients undergoing TRPB.
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